Drugs / TP-0184
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03429218 | Jul 2018 → Mar 2021 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04623996 | Dec 2020 → Apr 2021 | myelodysplastic syndrome | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-0184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03429218 ↗ |
| Action | Inhibit | “TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase” NCT03429218 ↗ |
| Route | Oral | “Weekly dose of TP-0184 by oral administration” NCT03429218 ↗ |
| Target | ACRV1 | “TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase” NCT03429218 ↗ |
| Target | ALK2 | “TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase” NCT03429218 ↗ |